Looks like you clickedhttps://www.businesswire.com/news/home/20211202006066/en/Phase-III-Investigational-Trial-of-NUBEQA%C2%AE-darolutamide-in-Combination-with-Docetaxel-and-Androgen-Deprivation-Therapy-ADT-Meets-Primary-Endpoint-of-Significantly-Increasing-Overall-Survival-OS-in-Patients-with-mHSPC
If you do not want to visit that page, you can close this browser tab.
